Quarterly report pursuant to Section 13 or 15(d)

Inventories

v3.20.2
Inventories
3 Months Ended
Aug. 31, 2020
Inventory Disclosure [Abstract]  
Inventories
Note 4 –
Inventories
The Company’s inventory as of August 31, 2020 and May 31, 2020 was $58.5 million and $19.1 million , respectively. Inventory as of August 31, 2020 consisted of raw materials purchased and work
-
in
-
progress
inventory
related to
 the commercial
 production
of pre-launch inventories
of leronlimab to support the Company’s expected approval of the product as a combination therapy for HIV patients in the United States. The Company believes that material uncertainties related to the ultimate regulatory approval of leronlimab for commercial sale have been significantly reduced based on positive data from
 the
Phase 3 clinical trial results, and information gathered
from pre-filing meetings
with the FDA for the BLA. The BLA was initially submitted with the FDA in April 2020 and the BLA submission was completed on May 11, 2020. In July 2020, the Company received a Refusal to File letter from the FDA regarding its BLA filing requesting additional information, and the Company requested a Type A meeting to discuss the FDA’s request for additional information
.
 
The FDA did not schedule a Type A meeting, but requested the Company submit all questions regarding the filing in writing. In September 2020, the Company submitted its questions to the FDA, received written responses, and held a telephonic meeting with the FDA to obtain further clarity on what additional information was required with respect to the BLA filing. The Company is working to provide the information required by the FDA in order to resubmit the BLA, which it anticipates will occur by the end of the calendar year 2020.
Inventories as of August 31, 2020 and May 31, 2020 are presented below (in thousands):
 
    
August 31, 2020
    
May 31, 2020
 
Raw materials
   $ 20,263      $ 19,147  
Work
-
in
-
pro
gress
     38,211         
Total
   $ 58,474      $ 19,147